SynOx Therapeutics

PITCH

At SynOx, we understand the power of being in control of your own journey in the treatment of your disease. Our mission is to establish emactuzumab as a best-in-class drug of choice to address the unmet needs, and improve the quality of life, of as many patients as possible. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases. SynOx Therapeutics was established in November 2020 following the licensing from Roche of the exclusive worldwide rights to emactuzumab, a potentially best-in-class CSF-1R monoclonal antibody. Emactuzumab has a well-tolerated safety profile and has shown promising efficacy in patients suffering from TGCT, a rare and debilitating disease that causes significant pain and disability. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation. It is backed by a strong syndicate of premier life sciences investors.